Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes.

BACKGROUND A multitude of biomarkers have been suggested for early risk-assessment in patients admitted to the emergency department with suspected acute coronary syndromes. We used logistic regression synergistically with classification and regression tree (CART) analysis to define a multimarker strategy and the cut-off values and sequencing needed to optimize risk stratification in a low to moderate risk population of the emergency department. METHODS 432 unselected patients (59.7+/-14.5 y, 60.4% male) admitted to the emergency department (ED) with acute coronary syndromes (ACS) were enrolled. Cardiac troponin I (cTnI), N-terminal pro-B-Type natriuretic peptide (NT-proBNP), high sensitivity C-reactive protein (hsCRP), placental growth factor (PlGF), lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and D-dimers were measured by immunoassay and whole blood choline (WBCHO) and plasma choline (PLCHO) were measured using LC/MS from baseline samples. Logistic regression and CART analysis were used to define the importance of the various biomarkers tested and to define their hierarchy with respect to the prediction of major adverse cardiac events (MACE; cardiac death, non-fatal MI, unstable angina, CHF requiring admission, urgent PCI and CABG) over the 42-day follow-up period. RESULTS A combination of NT-proBNP, WBCHO and Lp-PLA2 with cutoffs identified by CART-analysis was optimal for risk-stratification and superior to all other possible combinations of markers. Increased concentrations of both NT-proBNP (>1400 ng/l) and WBCHO (>21 micromol/l) identified patients with very high risk (RR=2.4, 39% primary endpoint) while low concentrations of NT-proBNP (< or = 1400 ng/l), WBCHO (< or = 17 micromol/l) and LP-PLA2 (< or = 210 microg/l) indicated very low risk (0% primary endpoint). WBCHO > 17 micromol/l additionally identified a subgroup with intermediate risk (RR=3.0, 13.5% primary endpoint) in patients with NT-proBNP concentrations < or = 1400 ng/l. Troponin when increased was highly prognostic but was not often positive in this early cohort. CONCLUSIONS A multimarker strategy defined synergistically by logistic regression and by classification and regression tree (CART) analysis can stratify patients into risk groups ranging from very low risk (0% MACE) to very high risk (39.5% MACE) based on admission values.

[1]  M. Al-Nozha,et al.  Haemostatic variables in patients with unstable angina. , 1994, International journal of cardiology.

[2]  N. Kleiman,et al.  Soluble CD40 ligand in acute coronary syndromes. , 2003, The New England journal of medicine.

[3]  A. Hofman,et al.  Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study , 2005, Circulation.

[4]  M. Hadamitzky,et al.  Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.

[5]  M. Möckel,et al.  Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. , 2003, The American journal of cardiology.

[6]  M. Emdin,et al.  Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natr , 2004, Clinical chemistry and laboratory medicine.

[7]  A. Siegbahn,et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.

[8]  D. Morrow,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes☆ , 2002 .

[9]  K. Huber,et al.  N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. , 2004, Journal of the American College of Cardiology.

[10]  C. Heeschen,et al.  Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.

[11]  K. Lackner,et al.  Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency room. , 2005, Clinical chemistry.

[12]  M. Möckel,et al.  Whole-blood hypercholinemia and coronary instability and thrombosis. , 2005, Clinical chemistry.

[13]  Leo Breiman,et al.  Classification and Regression Trees , 1984 .

[14]  L. Wallentin,et al.  Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. , 2005, Journal of the American College of Cardiology.

[15]  A. Wu,et al.  Evaluation of imprecision for cardiac troponin assays at low-range concentrations. , 2004, Clinical chemistry.

[16]  M. Sabatine,et al.  Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial , 2006, Circulation.

[17]  A. Laggner,et al.  Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room. , 2002, Clinical chemistry.

[18]  F. Apple,et al.  Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. , 2007, Clinical chemistry.

[19]  Prof. Dr. med. C. W. Hamm,et al.  Leitlinien: Akutes Koronarsyndrom (ACS) , 2004, Zeitschrift für Kardiologie.

[20]  A. Go,et al.  The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. , 2001, Journal of the American College of Cardiology.

[21]  C. Hamm,et al.  [Guidelines: acute coronary syndrome (ACS). 1: ACS without persistent ST segment elevations]. , 2004, Zeitschrift fur Kardiologie.

[22]  M. Möckel,et al.  Whole blood choline and plasma choline in acute coronary syndromes: prognostic and pathophysiological implications. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[23]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[24]  C. Heeschen,et al.  Prognostic value of placental growth factor in patients with acute chest pain. , 2004, JAMA.

[25]  TorbjørnOmland,et al.  N-Terminal Pro-B–Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes , 2002 .

[26]  E. Antman,et al.  B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. , 2004, Journal of the American College of Cardiology.

[27]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[28]  J. Kruskal,et al.  Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. , 1987, The New England journal of medicine.

[29]  Robert H Christenson,et al.  Stratus CS cardiac troponin I method: performance characteristics including imprecision at low concentrations. , 2004, Clinical biochemistry.

[30]  R. Califf,et al.  Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. , 2005, JAMA.

[31]  B. Lindahl,et al.  N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. , 2002, Journal of the American College of Cardiology.

[32]  J. Manson,et al.  A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. , 2001, Journal of the American College of Cardiology.

[33]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[34]  D. Tschoepe,et al.  Angina intensity is not different in diabetic and non-diabetic patients with acute myocardial infarction , 2003, Zeitschrift für Kardiologie.

[35]  Fred S Apple,et al.  Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. , 2005, Clinical chemistry.

[36]  H. Brenner,et al.  Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. , 2005, Atherosclerosis.

[37]  F. Cambien,et al.  Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. , 2003, Journal of lipid research.

[38]  C. Heeschen,et al.  Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. , 2005, Journal of the American College of Cardiology.

[39]  C. Heeschen,et al.  Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. , 2006, Journal of the American College of Cardiology.

[40]  E. Brilakis,et al.  Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. , 2005, European heart journal.

[41]  C. Packard,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease , 2000 .

[42]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[43]  Heejung Bang,et al.  Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study , 2004, Circulation.

[44]  J. Hinde,et al.  Models for diagnosing chest pain: is CART helpful? , 1997, Statistics in medicine.